Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine. 

Cardiology Month in Review: February 2024

Anticoagulation and antiplatelet therapy show no significant difference in recurrent stroke risk among patients with cryptogenic stroke and evidence of atrial cardiopathy.

ARCADIA: Apixaban Not Superior to Aspirin in Reducing Recurrent Stroke Risk 

Our November 2023 month in review for cardiology features highlights from AHA 2023, new atrial fibrillation guidelines, a pair of historic approvals from the FDA, and more!

Cardiology Month in Review: November 2023

Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more. 

ACC/AHA Release Updated Atrial Fibrillation Guidelines for 2023

Bayer has announced the IDMC for OCEANIC-AF trial has recommended the trial be discontinued as a result of inferior efficacy. 

Bayer Halts Asundexian AFib Trial, OCEANIC-AF, for Inferior Efficacy

Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF. 

Interpreting the Clinical Benefit of Abelacimab for Atrial Fibrillation, with Christian Ruff, MD, MPH

Results of the ARTESIA trial suggest apixaban lowered stroke risk by 37% in subclinical atrial fibrillation versus aspirin, but increased major bleeding risk.

Apixaban Lowers Stroke Risk, but Increases Major Bleeding Risk in Subclinical AFib

Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.

Abelacimab Significantly Reduces Bleeding in People with Atrial Fibrillation, Study Finds

In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates. 

Etripamil Nasal Spray Outperforms Placebo for AFib with Rapid Ventricular Rate

Announced by Milestone Pharmaceuticals on October 24, 2023, the New Drug Application includes positive results on etripamil from the pivotal phase 3 RAPID trial. 

Arrhythmia